ArticleMikrochimica acta2023
Chitosan/luminol/AgNPs nanocomposite for electrochemiluminescent determination of prostate-specific antigen.
Article in Mikrochimica acta, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 24 citations in OpenAlex.
- Advances in nanomaterial-enhanced immunosensors for ultra-sensitive tumor marker detection: Enabling early cancer diagnostics.Frontiers in chemistry · 2026Review
- Nanoparticle-based drug delivery systems in urologic oncology: From targeted therapy to precision theranostics.Materials today. Bio · 2025Review
- Recent Progress of Polymer-Based Biosensors for Cancer Diagnostic Applications: Natural versus Synthetic Polymers.ACS omega · 2025Review
- Biosensors; a novel concept in real-time detection of autophagy.Biosensors & bioelectronics · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
Abstract
A green, environmentally friendly protocol was developed for ultrasensitive and highly specific recognition of prostate-specific antigen (PSA) based on the ECL effect of luminol supported by chitosan-silver nanoparticles (CS/AgNPs) nanocomposites. The transducing surface was fabricated through two consecutive electrodeposition steps of gold nanoparticles (AuNPs) and chitosan (CS)-AgNPs-luminol electrochemiluminophore onto the glassy carbon electrode. In addition to an appropriate desirable biocompatibility, the electrochemical synthesis presents low-cost preparation and ultrafast determination opportunity. AgNPs play a linking role to attach luminol, as an ECL agent to the CS support via donor-acceptor bonds between Ag atoms with NH groups of luminol and CS. Also, AgNPs can amplify the ECL intensity as a consequence of their excellent specific surface area and conductivity. To enhance the performance of the nanobiosensor, AuNPs were also used due to their high-specific surface area and excellent affinity toward amine groups of CS. Based on this high-performance analysis strategy, ultrasensitive screening of PSA was attained with a desirable limit of detection of 0.6 ng mL
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.